Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.

CONCLUSION: Emicizumab enhances coagulation potential in PwMHA. Assessment of ex vivo coagulant activity of emicizumab could be helpful for predicting coagulant potentials prior to treatment in these patients. PMID: 32384547 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32384547?dopt=Abstract

Source: Thrombosis and Haemostasis - May 7, 2020 Category: Hematology Authors: Nakajima Y, Nogami K, Yada K, Furukawa S, Noguchi-Sasaki M, Hirata M, Shima M Tags: Thromb Haemost Source Type: research